Calliditas Therapeutics AB Overview

Calliditas Therapeutics AB Selling, General & Admin

Selling, General & Admin expenses for CALT.

Quarterly SG&A Expenses

$419.82M

↑ 56.28% YoY

As of Jun 30, 2024

Annual SG&A Expenses (TTM)

$1.31B

↑ 35.71% YoY

Trailing 12 months ending Jun 30, 2024

Average SG&A Expenses (Comparison Companies)

Selling, General & Admin History

Selling, General & Admin Comparison

Annual Selling, General & Admin Growth Rate (%)

Annual Selling, General & Admin Growth (Absolute)

Jump to metric

Total Revenue Cost of Revenue Gross Profit Research & Development Selling, General & Admin Operating Income Other Income Expense Net EBIT Income Tax Net Income Profit Margin